Home / Recalls
Consumer Product Recalls
127,244 recalls from the U.S. Consumer Product Safety Commission, newest first.
April 8, 2026Medical DevicesFDA
Oxoid Australia Pty Limited recalls OXOID MICROBACT IDENTIFICATION KITS, Listeria 12L Kit, 20 Tests; Listeria identification sysystem
Hazard: Oxoid Ltd., part of Thermo Fisher Scientific, confirmed that Microbact 12L Kit 20 Tests MB1128A lot 4494873 may identify incorrect organism due to inconclusive result from ambiguous color reactions in wells.
April 8, 2026Medical DevicesFDA
Burlington Medical, LLC recalls Burlington Medical, Kilt Blockers.
Hazard: Potential for attenuation degradation over time, decreasing the lifespan.
April 8, 2026Medical DevicesFDA
Burlington Medical, LLC recalls Burlington Medical, Blockers.
Hazard: Potential for attenuation degradation over time, decreasing the lifespan.
April 8, 2026Medical DevicesFDA
Burlington Medical, LLC recalls Burlington Medical, Demi Half Aprons.
Hazard: Potential for attenuation degradation over time, decreasing the lifespan.
April 8, 2026Medical DevicesFDA
Burlington Medical, LLC recalls Burlington Medical, Half Aprons.
Hazard: Potential for attenuation degradation over time, decreasing the lifespan.
April 8, 2026Medical DevicesFDA
Burlington Medical, LLC recalls Burlington Medical, Leg Wraps.
Hazard: Potential for attenuation degradation over time, decreasing the lifespan.
April 8, 2026Medical DevicesFDA
Burlington Medical, LLC recalls Burlington Medical, Caps.
Hazard: Potential for attenuation degradation over time, decreasing the lifespan.
April 8, 2026Medical DevicesFDA
Burlington Medical, LLC recalls Burlington Medical, Protective Sleeves.
Hazard: Potential for attenuation degradation over time, decreasing the lifespan.
April 8, 2026Medical DevicesFDA
Burlington Medical, LLC recalls Burlington Medical, BAT (Breast, Axilla and Thyroid) Coverage.
Hazard: Potential for attenuation degradation over time, decreasing the lifespan.
April 8, 2026Medical DevicesFDA
Burlington Medical, LLC recalls Burlington Medical, Wrap Aprons.
Hazard: Potential for attenuation degradation over time, decreasing the lifespan.
April 8, 2026Medical DevicesFDA
Burlington Medical, LLC recalls Burlington Medical, Frontal Aprons
Hazard: Potential for attenuation degradation over time, decreasing the lifespan.
April 8, 2026Medical DevicesFDA
Burlington Medical, LLC recalls Burlington Medical, Kilt
Hazard: Potential for attenuation degradation over time, decreasing the lifespan.
April 8, 2026Medical DevicesFDA
Burlington Medical, LLC recalls Burlington Medical, Vest
Hazard: Potential for attenuation degradation over time, decreasing the lifespan.
April 8, 2026Medical DevicesFDA
Burlington Medical, LLC recalls Burlington Medical, Thyroid Shield.
Hazard: Potential for attenuation degradation over time, decreasing the lifespan.
April 8, 2026Medical DevicesFDA
Medtronic MiniMed, Inc. recalls Paradigm REAL-Time Veo Insulin Pump (MMT-554, MMT-754)
Hazard: All Medtronic MiniMed infusion pumps (Paradigm series, 600 series, and BLE 700 series) were found to be affected by unintended over- and under-delivery of insulin when the pump is elevated or lowered relative to the infusion site, respectively, because of changes in gravitational force impacting hydrostatic and hydrodynamic pressures. Insulin over-delivery, which can occur when the pump is elevated relative to the infusion site, can result in severe hypoglycemia, altered mental status, seizure, coma, or death. An under-delivery of insulin, which can occur at lowered pump height conditions relative to the infusion site, can result in severe hyperglycemia, dehydration, diabetic ketoacidosis, or death.
April 8, 2026Medical DevicesFDA
Medtronic MiniMed, Inc. recalls MiniMed 530G Insulin Pump (MMT-551, MMT-751)
Hazard: All Medtronic MiniMed infusion pumps (Paradigm series, 600 series, and BLE 700 series) were found to be affected by unintended over- and under-delivery of insulin when the pump is elevated or lowered relative to the infusion site, respectively, because of changes in gravitational force impacting hydrostatic and hydrodynamic pressures. Insulin over-delivery, which can occur when the pump is elevated relative to the infusion site, can result in severe hypoglycemia, altered mental status, seizure, coma, or death. An under-delivery of insulin, which can occur at lowered pump height conditions relative to the infusion site, can result in severe hyperglycemia, dehydration, diabetic ketoacidosis, or death.
April 8, 2026Medical DevicesFDA
Medtronic MiniMed, Inc. recalls Paradigm REAL-Time Revel Insulin Pump (MMT-523, MMT-723)
Hazard: All Medtronic MiniMed infusion pumps (Paradigm series, 600 series, and BLE 700 series) were found to be affected by unintended over- and under-delivery of insulin when the pump is elevated or lowered relative to the infusion site, respectively, because of changes in gravitational force impacting hydrostatic and hydrodynamic pressures. Insulin over-delivery, which can occur when the pump is elevated relative to the infusion site, can result in severe hypoglycemia, altered mental status, seizure, coma, or death. An under-delivery of insulin, which can occur at lowered pump height conditions relative to the infusion site, can result in severe hyperglycemia, dehydration, diabetic ketoacidosis, or death.
April 8, 2026Medical DevicesFDA
Medtronic MiniMed, Inc. recalls Paradigm REAL-Time Insulin Pump (MMT-522, MMT-722)
Hazard: All Medtronic MiniMed infusion pumps (Paradigm series, 600 series, and BLE 700 series) were found to be affected by unintended over- and under-delivery of insulin when the pump is elevated or lowered relative to the infusion site, respectively, because of changes in gravitational force impacting hydrostatic and hydrodynamic pressures. Insulin over-delivery, which can occur when the pump is elevated relative to the infusion site, can result in severe hypoglycemia, altered mental status, seizure, coma, or death. An under-delivery of insulin, which can occur at lowered pump height conditions relative to the infusion site, can result in severe hyperglycemia, dehydration, diabetic ketoacidosis, or death.
April 8, 2026Medical DevicesFDA
Medtronic MiniMed, Inc. recalls Paradigm Insulin Pump (MMT-712, MMT-715)
Hazard: All Medtronic MiniMed infusion pumps (Paradigm series, 600 series, and BLE 700 series) were found to be affected by unintended over- and under-delivery of insulin when the pump is elevated or lowered relative to the infusion site, respectively, because of changes in gravitational force impacting hydrostatic and hydrodynamic pressures. Insulin over-delivery, which can occur when the pump is elevated relative to the infusion site, can result in severe hypoglycemia, altered mental status, seizure, coma, or death. An under-delivery of insulin, which can occur at lowered pump height conditions relative to the infusion site, can result in severe hyperglycemia, dehydration, diabetic ketoacidosis, or death.
April 8, 2026Medical DevicesFDA
Medtronic MiniMed, Inc. recalls MiniMed 620G Insulin Pump (MMT-1750)
Hazard: All Medtronic MiniMed infusion pumps (Paradigm series, 600 series, and BLE 700 series) were found to be affected by unintended over- and under-delivery of insulin when the pump is elevated or lowered relative to the infusion site, respectively, because of changes in gravitational force impacting hydrostatic and hydrodynamic pressures. Insulin over-delivery, which can occur when the pump is elevated relative to the infusion site, can result in severe hypoglycemia, altered mental status, seizure, coma, or death. An under-delivery of insulin, which can occur at lowered pump height conditions relative to the infusion site, can result in severe hyperglycemia, dehydration, diabetic ketoacidosis, or death.
April 8, 2026Medical DevicesFDA
Medtronic MiniMed, Inc. recalls MiniMed 740G Insulin Pump (MMT-1811, MMT-1812, MMT-1861, MMT-1862)
Hazard: All Medtronic MiniMed infusion pumps (Paradigm series, 600 series, and BLE 700 series) were found to be affected by unintended over- and under-delivery of insulin when the pump is elevated or lowered relative to the infusion site, respectively, because of changes in gravitational force impacting hydrostatic and hydrodynamic pressures. Insulin over-delivery, which can occur when the pump is elevated relative to the infusion site, can result in severe hypoglycemia, altered mental status, seizure, coma, or death. An under-delivery of insulin, which can occur at lowered pump height conditions relative to the infusion site, can result in severe hyperglycemia, dehydration, diabetic ketoacidosis, or death.
April 8, 2026Medical DevicesFDA
Medtronic MiniMed, Inc. recalls MiniMed 720G Insulin Pump (MMT-1809, MMT-1810, MMT-1859, MMT-1860, MMT-1867)
Hazard: All Medtronic MiniMed infusion pumps (Paradigm series, 600 series, and BLE 700 series) were found to be affected by unintended over- and under-delivery of insulin when the pump is elevated or lowered relative to the infusion site, respectively, because of changes in gravitational force impacting hydrostatic and hydrodynamic pressures. Insulin over-delivery, which can occur when the pump is elevated relative to the infusion site, can result in severe hypoglycemia, altered mental status, seizure, coma, or death. An under-delivery of insulin, which can occur at lowered pump height conditions relative to the infusion site, can result in severe hyperglycemia, dehydration, diabetic ketoacidosis, or death.
April 8, 2026Medical DevicesFDA
Medtronic MiniMed, Inc. recalls MiniMed 700G Insulin Pump (MMT-1801, MMT-1805, MMT-1850, MMT-1851)
Hazard: All Medtronic MiniMed infusion pumps (Paradigm series, 600 series, and BLE 700 series) were found to be affected by unintended over- and under-delivery of insulin when the pump is elevated or lowered relative to the infusion site, respectively, because of changes in gravitational force impacting hydrostatic and hydrodynamic pressures. Insulin over-delivery, which can occur when the pump is elevated relative to the infusion site, can result in severe hypoglycemia, altered mental status, seizure, coma, or death. An under-delivery of insulin, which can occur at lowered pump height conditions relative to the infusion site, can result in severe hyperglycemia, dehydration, diabetic ketoacidosis, or death.
April 8, 2026Medical DevicesFDA
Medtronic MiniMed, Inc. recalls MiniMed 640G Insulin Pump (MMT-1711, MMT-1712, MMT-1751, MMT-1752)
Hazard: All Medtronic MiniMed infusion pumps (Paradigm series, 600 series, and BLE 700 series) were found to be affected by unintended over- and under-delivery of insulin when the pump is elevated or lowered relative to the infusion site, respectively, because of changes in gravitational force impacting hydrostatic and hydrodynamic pressures. Insulin over-delivery, which can occur when the pump is elevated relative to the infusion site, can result in severe hypoglycemia, altered mental status, seizure, coma, or death. An under-delivery of insulin, which can occur at lowered pump height conditions relative to the infusion site, can result in severe hyperglycemia, dehydration, diabetic ketoacidosis, or death.
April 8, 2026Medical DevicesFDA
Medtronic MiniMed, Inc. recalls MiniMed 770G Insulin Pump (MMT-1880, MMT-1881, MMT-1882, MMT-1890, MMT-1891, MMT-1892)
Hazard: All Medtronic MiniMed infusion pumps (Paradigm series, 600 series, and BLE 700 series) were found to be affected by unintended over- and under-delivery of insulin when the pump is elevated or lowered relative to the infusion site, respectively, because of changes in gravitational force impacting hydrostatic and hydrodynamic pressures. Insulin over-delivery, which can occur when the pump is elevated relative to the infusion site, can result in severe hypoglycemia, altered mental status, seizure, coma, or death. An under-delivery of insulin, which can occur at lowered pump height conditions relative to the infusion site, can result in severe hyperglycemia, dehydration, diabetic ketoacidosis, or death.
April 8, 2026Medical DevicesFDA
Medtronic MiniMed, Inc. recalls MiniMed 780G Insulin Pump (MMT-1884, MMT-1885, MMT-1886, MMT-1894, MMT-1895, MMT-1896)
Hazard: All Medtronic MiniMed infusion pumps (Paradigm series, 600 series, and BLE 700 series) were found to be affected by unintended over- and under-delivery of insulin when the pump is elevated or lowered relative to the infusion site, respectively, because of changes in gravitational force impacting hydrostatic and hydrodynamic pressures. Insulin over-delivery, which can occur when the pump is elevated relative to the infusion site, can result in severe hypoglycemia, altered mental status, seizure, coma, or death. An under-delivery of insulin, which can occur at lowered pump height conditions relative to the infusion site, can result in severe hyperglycemia, dehydration, diabetic ketoacidosis, or death.
April 8, 2026Medical DevicesFDA
Medtronic MiniMed, Inc. recalls MiniMed 630G Insulin Pump (MMT-1714, MMT-1715, MMT-1754, MMT-1755)
Hazard: All Medtronic MiniMed infusion pumps (Paradigm series, 600 series, and BLE 700 series) were found to be affected by unintended over- and under-delivery of insulin when the pump is elevated or lowered relative to the infusion site, respectively, because of changes in gravitational force impacting hydrostatic and hydrodynamic pressures. Insulin over-delivery, which can occur when the pump is elevated relative to the infusion site, can result in severe hypoglycemia, altered mental status, seizure, coma, or death. An under-delivery of insulin, which can occur at lowered pump height conditions relative to the infusion site, can result in severe hyperglycemia, dehydration, diabetic ketoacidosis, or death.
April 8, 2026Medical DevicesFDA
Medtronic MiniMed, Inc. recalls MiniMed 670G Insulin Pump (MMT-1760, MMT-1761, MMT-1762, MMT-1780, MMT-1781, MMT-1782)
Hazard: All Medtronic MiniMed infusion pumps (Paradigm series, 600 series, and BLE 700 series) were found to be affected by unintended over- and under-delivery of insulin when the pump is elevated or lowered relative to the infusion site, respectively, because of changes in gravitational force impacting hydrostatic and hydrodynamic pressures. Insulin over-delivery, which can occur when the pump is elevated relative to the infusion site, can result in severe hypoglycemia, altered mental status, seizure, coma, or death. An under-delivery of insulin, which can occur at lowered pump height conditions relative to the infusion site, can result in severe hyperglycemia, dehydration, diabetic ketoacidosis, or death.
April 8, 2026Medical DevicesFDA
Civco Medical Instruments Co. Inc. recalls eTRAX Needle Sensor - 18G (for Aurora Trackers), Part Number 667-159
Hazard: There was an error in inspection and programming of the eTRAX needle sensor for Aurora trackers. The result is a potential for the needle tip position to be incorrectly identified on the user interface.
April 8, 2026Medical DevicesFDA
Civco Medical Instruments Co. Inc. recalls eTRAX Needle Sensor - 16G(for Aurora Trackers), Part Number 667-158
Hazard: There was an error in inspection and programming of the eTRAX needle sensor for Aurora trackers. The result is a potential for the needle tip position to be incorrectly identified on the user interface.